Where biologic hip injections fit in your pathway

Ongoing hip joint pain after a course of exercise-based physiotherapy (often 6–12 weeks) and simple pain relief can leave a common “what next?” gap: symptoms are affecting walking and sleep, but the hip is not yet at the point where hip replacement feels inevitable. In that in-between stage—particularly when X‑rays or MRI suggest early to moderate hip osteoarthritis—biologic (orthobiologic) injections are sometimes considered as a hip‑preservation step rather than a final cure.

Biologic hip injections are treatments made from a person’s own tissue—most commonly blood (platelet-rich plasma, PRP), fat (micro‑fragmented adipose tissue, mFAT, including Lipogems-style processing), or bone marrow (bone marrow aspirate concentrate, BMAC, or related preparations). The material is processed and then injected into the hip joint with the aim of reducing inflammation and supporting the body’s own repair processes, rather than acting as a purely synthetic drug. Systematic reviews published in 2022 and 2025 describe overall improvements in patient-reported pain and hip function after PRP and cell-based injections, but emphasise that studies vary widely in how the products are prepared and measured, which limits certainty when comparing results across clinics or techniques.

In practical terms, these are image‑guided outpatient injections (most commonly ultrasound‑guided) into the hip joint, with people going home the same day. Across published hip PRP trials and hip BMAC reviews up to 2024, serious complications are uncommon or not reported, but this does not remove the need for proper assessment and sterile technique. The key point is that an injection appointment is not the same pathway as an operation, and expectations are usually set around symptom relief and function, not “making the hip normal again”.

Disease stage matters. The better results reported in orthobiologic reviews tend to be in earlier-stage hip osteoarthritis rather than severe, end‑stage joint damage. In more advanced hips, injections may still help pain in some cases, but hip replacement remains the more predictable option for restoring walking tolerance and quality of life when the joint is badly worn. Even in early–moderate cohorts, some patients still progress to hip replacement within a few years, so biologic injections are often framed as a way to attempt to delay surgery rather than to guarantee avoiding it.

Within a hip‑only pathway such as Lincolnshire Hip, biologic injections sit between conservative care and surgery: assessment and imaging can be done locally in Grantham or Sleaford, with ultrasound‑guided injections offered when appropriate, and hip replacement surgery reserved for cases where symptoms and joint damage have moved beyond what injections are likely to help (performed at Weymouth Street Hospital in London).

PRP injections for the hip joint in the UK

PRP (platelet‑rich plasma) is a way of using a concentrated portion of a person’s own blood to try to calm inflammation and support the body’s repair signalling around an arthritic hip joint. In UK clinics, the appointment is commonly described as an ultrasound‑guided injection pathway using an autologous blood product rather than a drug manufactured in a factory. [trafilatura:https%3A%2F%2Fwww.mskclinic.co.uk%2Fpost%2Fprp-injections-for-hip-osteoarthritis-london-kent; trafilatura:https%3A%2F%2Fpracticeplusgroup.com%2Ftreatments%2Fhip-surgery%2Fplatelet-rich-plasma-injections%2F]

From blood draw to hip joint injection

On the day, PRP is typically prepared from a small blood sample taken shortly before the injection. The sample is processed to increase the concentration of platelets (this is usually done by spinning the sample in a centrifuge), producing a smaller volume of platelet‑rich plasma. The PRP is then placed into the hip joint under ultrasound guidance, as a “walk‑in/walk‑out” outpatient procedure described by UK private providers as taking roughly 45–60 minutes in total. [trafilatura:https%3A%2F%2Fwww.mskclinic.co.uk%2Fpost%2Fprp-injections-for-hip-osteoarthritis-london-kent; trafilatura:https%3A%2F%2Fpracticeplusgroup.com%2Ftreatments%2Fhip-surgery%2Fplatelet-rich-plasma-injections%2F]

What research suggests for hip osteoarthritis (short to mid term)

Evidence for PRP in hip osteoarthritis is strongest in the first year after injection, with far less certainty beyond that. A 2024 systematic review of randomised clinical trials (five RCTs up to October 2022) reported that PRP injections were associated with pain reduction and functional improvement in hip osteoarthritis, and noted no major adverse events in the included trials. [ai4scholar:bd311679dd7ec2117bc3585852abb34702905958]

A separate 2024 review that covered both hip and knee osteoarthritis similarly concluded that PRP is generally effective compared with baseline, but found that superiority over comparators such as hyaluronic acid is inconsistent across studies and protocols. That same review highlighted the ongoing issue for hip PRP research: preparation methods, dosing schedules and outcome measures differ between trials, making like‑for‑like comparison difficult. [trafilatura:https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11488654%2F]

Trial data: PRP versus hyaluronic acid at 6 months

One commonly cited randomised trial enrolled 105 people with grade 2–3 hip osteoarthritis and compared two ultrasound‑guided injections of PRP, hyaluronic acid (HA), or PRP combined with HA. At 6 months, the PRP and PRP+HA groups showed greater improvements in pain and hip‑specific outcome scores than the HA‑only group, and the combination did not show a clear added benefit over PRP alone. [trafilatura:https%3A%2F%2Flink.springer.com%2Farticle%2F10.1186%2Fs12891-022-05787-8]

PRP alone versus PRP plus hyaluronic acid

Whether adding HA improves PRP results in the hip has been questioned by later pooled analyses. A 2025 systematic review and meta‑analysis (190 patients) reported that PRP+HA was associated with higher pain scores at 3 and 12 months than PRP alone, with no functional advantage—supporting PRP monotherapy as the usual default where intra‑articular PRP is chosen for hip osteoarthritis. [ai4scholar:388d208499b60f3682a6868e135e8be2d095e0ea]

The main uncertainties that still matter

Even when pain and function improve at 6–12 months, the evidence base remains limited in three practical ways:

• PRP is not one standard product. Systematic reviews of hip orthobiologics repeatedly note heterogeneity in PRP preparation (including platelet concentration and whether leukocytes are included), and differences in injection number and interval. That heterogeneity weakens confidence when comparing results between studies and between clinics. [ai4scholar:31dfe04c60b44016bf2773cacbcbbfd86422ce4d; ai4scholar:d913aa768950a43fa203093954a349f25ffde3e4]
• Long‑term follow‑up is sparse. Across hip PRP studies, follow‑up beyond roughly 1–2 years is uncommon, so it remains unclear how often benefits persist or whether repeat injections are needed on a planned schedule. [ai4scholar:bd311679dd7ec2117bc3585852abb34702905958; trafilatura:https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11488654%2F]
• Disease‑modifying effects are unproven. Current trial endpoints are mainly patient‑reported pain and function; robust evidence that PRP reliably alters structural progression or reduces future hip replacement rates is not yet established. [ai4scholar:31dfe04c60b44016bf2773cacbcbbfd86422ce4d]

UK access: NHS versus private, and where PRP sits in the Lincolnshire Hip pathway

To keep the clinical evidence narrative separate from provider details (and avoid “menu‑style” comparisons), practical access information is best summarised briefly. In the UK, PRP for hip osteoarthritis is commonly presented as a self‑pay treatment: Practice Plus Group states that PRP treatment is “not available for NHS patients”, and a London/Kent musculoskeletal clinic similarly notes PRP for hip osteoarthritis is “not currently available through the NHS”. The same clinic quotes pricing from about £780 per hip joint for a PRP package. [google_serp:organic:https%3A%2F%2Fpracticeplusgroup.com%2Ftreatments%2Fhip-surgery%2Fplatelet-rich-plasma-injections%2F; google_serp:organic:https%3A%2F%2Fwww.mskclinic.co.uk%2Fpost%2Fprp-injections-for-hip-osteoarthritis-london-kent; trafilatura:https%3A%2F%2Fwww.mskclinic.co.uk%2Fpost%2Fprp-injections-for-hip-osteoarthritis-london-kent]

Within Lincolnshire Hip’s current pathway, PRP is presented primarily for hip‑related groin and adductor problems (for example “Gilmore’s groin” and chronic adductor pain), rather than as the clinic’s main intra‑articular injection option for hip arthritis. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment. [trafilatura:https%3A%2F%2Flincolnshirehip.com]

mFAT and Lipogems for early hip arthritis

Fat‑derived biologic injections such as micro‑fragmented adipose tissue (mFAT) and Lipogems are typically considered when hip osteoarthritis is present but not yet “end stage” on imaging (for example Tönnis grade 1–2 in published series). To keep the clinical evidence clear and avoid interrupting it with service detail, provider‑specific practicalities are kept to a short note at the end of this section.

What mFAT (including Lipogems) is, in plain language

mFAT is prepared from a small sample of a person’s own fat, usually taken under local anaesthetic and then gently processed into tiny fat fragments in a closed system before being injected into the painful hip joint. Patient education material within the MSK Doctors network describes this as a way of delivering fat‑derived cells and signalling factors that may have anti‑inflammatory effects and may help support the body’s own repair processes in joints such as the hip, rather than acting as a simple painkiller. [trafilatura:https%3A%2F%2Fsearch.mskdoctors.com%2Fdoctors%2Fthomas-harrison%2Farticles%2Funderstanding-mfat-injections-and-lipogems-innovative-treatments-for-joint-pain]

“Lipogems” is commonly used as a brand name for a particular style of mFAT processing. In hip osteoarthritis, the published clinical literature is still relatively small; most outcomes are reported as changes in pain and hip‑specific scores at 6–12 months, with fewer datasets reaching 3 years. [ai4scholar:31dfe04c60b44016bf2773cacbcbbfd86422ce4d]

Who tends to be studied (and who tends to do better)

Across hip orthobiologic reviews, results are generally better in earlier‑stage disease than in more advanced joint damage, and this theme also appears in the adipose‑derived injection series. In practice, the most typical profile in studies is an adult with ongoing hip joint pain despite conservative treatment, imaging consistent with early to moderate osteoarthritis, and a preference to try to delay hip replacement rather than proceed directly to surgery. [ai4scholar:31dfe04c60b44016bf2773cacbcbbfd86422ce4d]

What the 1‑year MFAT pilot study found (30 patients)

A prospective pilot study followed 30 patients with Tönnis grade 1–2 hip osteoarthritis after a single ultrasound‑guided intra‑articular mFAT injection. Over follow‑up to 12 months, the group showed statistically significant improvements in VAS pain and Harris Hip Score at each time point reported, and 56.7% reached a minimal clinically important difference on WOMAC at both 6 and 12 months. The same study reported better outcomes in mild versus moderate hip osteoarthritis and noted no major complications. [trafilatura:https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12745173%2F]

This kind of dataset is useful for setting expectations: improvements can occur within a year for many people, but responses vary, and the strongest signals tend to be in hips that are less structurally worn at baseline (for example, Tönnis 1 rather than 2). [trafilatura:https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12745173%2F]

What the 3‑year follow‑up series suggests about durability (55 patients)

Longer follow‑up helps answer a different question: not just “does it help?”, but “how often does it hold up?”. In a 3‑year follow‑up series of 55 people with early–moderate hip osteoarthritis treated with a single mFAT injection, around half (28/55) did not require further treatment during the follow‑up window. In that same series, 10/55 had a second mFAT injection at roughly 1.7 years, while 17/55 progressed to total hip replacement at an average of about 1.4 years. The authors reported the best results in those starting with an Oxford Hip Score in an early–moderate range rather than more advanced functional limitation. [ai4scholar:a8777474b938fbf6c3c48cd02c6bc598e085ba6e]

Taken together, these numbers underline two realities that can coexist: some patients appear able to defer further intervention for several years after one injection, while a sizeable minority still progress to hip replacement within 1–3 years, particularly when baseline arthritis and disability are greater. [ai4scholar:a8777474b938fbf6c3c48cd02c6bc598e085ba6e]

MFAT alone versus MFAT plus PRP (147 hips at 1 year)

Combination approaches are sometimes marketed, but not all datasets show a clear “more is better” effect. A 1‑year observational intention‑to‑treat study of 147 patients treated with either MFAT alone or MFAT plus PRP reported significant improvements in VAS pain and Oxford Hip Score in both groups. More than 60% of patients achieved a ≥20‑point reduction in VAS pain, and overall outcomes were similar between MFAT and MFAT+PRP, suggesting limited incremental benefit from adding PRP for most hips in that cohort. [ai4scholar:788c9e3f947530e1cfa200b612a43fe22305a7ab]

Lipogems: small early hip series (6 patients)

For Lipogems specifically, a small early report of six patients with mild–moderate hip osteoarthritis (Tönnis 0–2) described improvements at 6 months after a single intra‑articular injection: mean Harris Hip Score rose from 67 to 85, WOMAC improved from 36 to 20, and pain VAS fell from 4.6 to 1.5, with no serious complications reported in that small series. The sample size (6 people) is too limited to generalise confidently, but it provides a concrete illustration of the kind of symptom‑and‑function outcomes reported in early hip cohorts. [trafilatura:https%3A%2F%2Fimageregenerative.com%2Fen%2Fscience%2Fmesenchymal-stem-cells-injection-in-hip-osteoarthritis-preliminary-results]

How this may be used within a Lincolnshire Hip pathway (brief note)

Within a hip‑only service such as Lincolnshire Hip, mFAT/Lipogems discussions typically sit in the “hip preservation” space for patients whose imaging and symptoms suggest early–moderate hip arthritis rather than end‑stage disease. A consultant assessment (often with imaging already available, or arranged locally in Grantham or Sleaford) is used to decide whether the pain pattern and joint status are consistent with an intra‑articular biologic option, and to flag situations where a painful hip is unlikely to be a good candidate and other pathways are more appropriate. [trafilatura:https%3A%2F%2Flincolnshirehip.com]

BMAC hip injections and who they may suit

Bone marrow aspirate concentrate (BMAC) is one of the main “cell-based” orthobiologic injections discussed for hip osteoarthritis. Rather than embedding web addresses in the flow of the text, the practical steps and the headline numbers from published hip studies are summarised in plain language below.

What BMAC is (and how it differs from PRP and mFAT)

BMAC is made from a small sample of a person’s own bone marrow. In most clinical protocols, marrow is drawn with a needle (commonly from the pelvic bone) under local anaesthetic, then processed to concentrate a mixture of cells and signalling factors. The concentrate is then placed into the hip joint using image guidance (often ultrasound) during the same visit. In broad terms, the “source material” is what distinguishes the main biologic options:

• PRP starts with a blood draw.
• mFAT/Lipogems starts with a small fat sample.
• BMAC starts with a marrow draw.

That difference matters in day-to-day decision-making because BMAC usually involves an additional needle-based collection step compared with PRP, but it may appeal to patients and clinicians looking for a marrow-derived orthobiologic option when symptoms and imaging suggest there is still “room to preserve” the hip joint rather than moving straight to replacement.

What the hip evidence shows so far

One of the most concrete datasets comes from a 31-patient hip osteoarthritis pilot study using a single intra-articular bone marrow aspirate (BMA) injection (closely related in concept to BMAC, but not identical in processing). Participants had Kellgren–Lawrence (KL) grade 2–4 hip osteoarthritis. At 6 and 12 months, the study reported statistically significant improvements in both pain (numeric rating scale) and function (HOOS-Jr). By 12 months, around 61% of patients achieved a ≥50% reduction in pain, and no serious adverse events were reported.

The same study also showed a severity pattern that aligns with wider orthobiologic reviews: responder rates were higher in KL2–3 hips than in more advanced disease. Reported responder rates were approximately 80% for KL2 and 71% for KL3, with lower response in KL4, which is often the “bone-on-bone” end of the spectrum.

Looking across the broader literature, a 2024 systematic review of BMAC for hip osteoarthritis identified five clinical studies totalling 182 patients. The review concluded that intra-articular BMAC was associated with short- to mid-term improvements in pain, function and quality of life, and it reported no adverse events in the included studies. At the same time, the review stressed that the evidence base remains limited: cohorts are generally small, many are uncontrolled, follow-up is often measured in months rather than years, and protocols vary between centres.

There is also early interest in marrow-based approaches that target bone as well as the joint space. A small intraosseous bone marrow concentrate case series included five people (mean age around 67) with Tönnis grade 2 hip osteoarthritis. It reported improvement in pain (mean VAS 7.6 → 2.4) and more than 50% functional improvement, with no procedure-related complications. With only five hips, this is best treated as feasibility data rather than definitive proof of benefit.

Who BMAC hip injections may suit

Across the BMA/BMAC hip datasets and orthobiologic systematic reviews, the profile that seems most consistent with a meaningful response is:

• Earlier to moderate hip osteoarthritis on imaging (often described as KL2–3), rather than very advanced KL4 disease.
• Symptoms that remain limiting at 6–12 months despite a course of non-operative care.
• A clear goal of improving pain and walking tolerance in the near term, with an understanding that symptom improvement does not yet equal proven long-term “disease modification” or guaranteed avoidance of hip replacement.

In more advanced arthritis, BMAC may still be considered by some clinicians as a symptom-focused option, but the available hip data suggest response rates drop as structural damage increases, and the published follow-up windows still leave uncertainty about durability beyond the first 1–2 years.

Where BMAC sits alongside other options at Lincolnshire Hip (brief note)

In a hip preservation conversation, BMAC is usually weighed alongside other orthobiologics (such as PRP and mFAT) in terms of tissue source, procedural steps, and the maturity of the hip-specific evidence. Within Lincolnshire Hip, the currently listed hip joint injection options for arthritis include Arthrosamid and ChondroFiller, while PRP is presented primarily for hip-related groin/adductor conditions; decisions about whether a marrow-derived option is appropriate are typically made after consultant assessment and review of imaging, with the aim of matching the injection type (or a surgical pathway) to the stage and pattern of hip joint disease.

What to expect from a biologic hip injection day

A biologic hip injection appointment can feel unfamiliar because there are two parts to it: confirming the pain is coming from the hip joint, and then delivering the chosen product accurately into that joint under ultrasound guidance. To keep the walk-through practical (and to avoid the repeated “provider plug” problem seen elsewhere in the draft), clinic-specific details for Lincolnshire Hip (Grantham and Sleaford) are grouped in a short note at the end of this section.

Before the injection is booked: making sure it is the hip joint

The pre-injection appointment is usually a consultant-led assessment of hip pain, combining an examination with a review of what has (and has not) helped so far—such as physiotherapy, tablets, or earlier injections. Imaging is often used to confirm the problem is intra-articular (within the hip joint) and to grade arthritis severity; Lincolnshire Hip also lists Open MRI as an option when imaging needs to be arranged locally.

On the day: a step-by-step outline

Most clinics follow a consistent sequence for PRP, mFAT/Lipogems, and marrow-derived injections, with the differences mainly being the collection step.

• Check-in and consent (same appointment) A short safety check and consent discussion typically covers: what is being injected (PRP, mFAT/Lipogems, or BMAC), what the aims are (symptom improvement rather than guaranteed structural change), and what side-effects can happen in the first few days.
• Positioning and skin preparation (hip joint) The hip is positioned to allow safe access for an ultrasound-guided needle path. The skin is cleaned, and the injection site is prepared in a sterile manner.
• Local anaesthetic (brief stinging) Local anaesthetic is used to numb the skin and deeper tissues. A brief sting or burn is common at this stage.
• Collection step (what differs between options) The “most memorable” discomfort often comes from the collection site rather than the hip joint itself:
• • PRP: a blood draw (often described as similar to a standard blood test).
  • mFAT/Lipogems: a small fat sample taken under local anaesthetic; bruising and tenderness can be felt around the harvest area for a short time.
  • BMAC/BMA-type injections: a bone marrow draw (commonly from the pelvis) under local anaesthetic; soreness can be felt at the draw site afterwards.
• Processing during the visit (minutes rather than days) The sample is prepared during the appointment (for example, concentrating the platelets for PRP, or processing fat or marrow into an injectate). Protocols vary between clinics and products.
• Ultrasound-guided hip joint injection (pressure rather than sharp pain) Ultrasound is used to guide placement into the hip joint. Many people describe a feeling of pressure or fullness as the injection goes in.
• Short observation, then home the same day Published UK clinic guidance describes PRP for hip arthritis as a walk-in/walk-out appointment, typically completed in 45–60 minutes, and this “outpatient, home the same day” pattern broadly matches how image-guided biologic injections are usually delivered.

The first few days: what is normal, and what is not

A temporary increase in aching or stiffness in the first few days is common after a hip joint injection, particularly with biologic products where the goal is to change the local inflammatory environment rather than to “numb” the joint. Simple pain relief is often used, and activity is usually adjusted down briefly.

Two early aftercare principles tend to matter most in week 1:

• Avoid heavy impact through the hip joint for a short period, especially if the joint is already sensitive on stairs or uneven ground.
• Keep the hip moving little and often, then build back gradually (a hip-focused rehabilitation plan is often used to regain walking tolerance and confidence).

Follow-up and rehabilitation (hip-specific)

Rehabilitation tends to be most effective when it is specific to the hip and the person’s functional goals—often improving gait pattern, hip range of motion, and strength around the hip (for example, gluteal and deep rotator control) rather than only general fitness. Follow-up is also where the response is reviewed against the starting point: walking distance, night pain, and key activities such as getting in and out of a car.

Risks: common nuisance effects vs rare serious problems

Across hip biologic injection studies, serious complications are uncommon in the published series, but they are not impossible.

• More common, usually self-limiting: temporary flare of hip pain, bruising at the blood/fat/marrow collection site, and short-lived stiffness.
• Less common but important: infection, significant bleeding, allergy to local anaesthetic, or new neurological symptoms.

In a 30-patient prospective study of ultrasound-guided mFAT for Tönnis 1–2 hip osteoarthritis, no major complications were reported at 12 months. In a 31-patient hip osteoarthritis study of a marrow-based injection, no serious adverse events were reported through 12 months. A 2024 systematic review of hip BMAC studies (5 studies; 182 patients) likewise reported no adverse events in the included cohorts, while also stressing that the overall evidence base is still limited by small study sizes.

Lincolnshire Hip practical note (kept to one place)

Lincolnshire Hip lists local appointments and injections in Grantham and Sleaford, with hip replacement surgery undertaken in London as a separate pathway when required. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for consultant assessment of hip pain and discussion of whether a biologic hip injection is an appropriate part of an overall hip care plan.

Choosing between injection, hip replacement and watchful waiting

Deciding what comes next for a painful hip joint usually comes down to three things: how worn the joint looks on imaging, how much the symptoms are limiting day-to-day life, and what time-horizon matters most (for example, the next 6–24 months versus the next decade). In this section, the clinic logistics are kept to one short note near the end so the close can stay focused on the decision itself.

How severe is my hip arthritis on imaging?

Published orthobiologic reviews consistently report a severity pattern: outcomes after PRP and cell-based injections are better in earlier-stage hip osteoarthritis than in advanced, end-stage disease, with “treatment success inversely proportional to OA severity” in one systematic review (2022). In practical terms, the more the hip is already structurally deformed and “bone-on-bone”, the less reliable any injection becomes as a meaningful next step, even if pain temporarily eases.

What am I hoping to achieve over the next 1–3 years?

Biologic hip injections are usually best framed as part of a hip preservation plan: aiming to reduce pain, improve walking tolerance and potentially delay hip replacement, rather than being a permanent fix for established arthritis. A useful reality-check comes from a three-year follow-up series of a single micro-fragmented adipose tissue (MFAT) injection in early–moderate hip osteoarthritis: among 55 people with 29–41 months follow-up, 28/55 needed no further treatment during that period, while 17/55 still went on to total hip replacement after an average of roughly 495 days (about 1.4 years). That split is not a promise of what will happen to any individual hip, but it illustrates the trade-off: symptom improvement can be meaningful, yet progression to replacement within 1–3 years remains a realistic possibility in a substantial minority.

How much has non-injection care already achieved?

Watchful waiting (or continued conservative care) tends to make the most sense when symptoms are fluctuating, when walking and sleep are still largely intact, or when recent changes (for example, a new strengthening plan over 8–12 weeks, a change in daily loading, or medication optimisation) have not yet had time to show their full effect. In contrast, when hip pain has remained persistently limiting despite a structured period of non-operative care, the decision more often becomes a choice between an injection as a time-buying strategy versus moving more directly to hip replacement.

What does my day-to-day function say (not just my scan)?

Two hips with similar X‑ray or MRI appearances can behave very differently. A 55-year-old with moderate changes but severe night pain and an inability to walk beyond 10 minutes may be a more reasonable “injection candidate” than a 70-year-old with similar imaging but manageable symptoms. Conversely, a hip that looks severely worn and is also causing constant pain, marked stiffness, and repeated sleep disturbance is less likely to respond well to biologics, even if earlier-stage hips often do.

When is hip replacement more likely to be the sensible next step?

Total hip replacement is widely used for end-stage hip arthritis pain (and in certain fractures), largely because it replaces the damaged joint surfaces rather than trying to modulate inflammation inside a failing joint. In decision terms, hip replacement is more likely to move to the front of the queue when there is a combination of:

• Constant severe pain (including regular night pain)
• Major stiffness and loss of basic function (for example, difficulty with stairs, shoes and socks, or getting in/out of a car)
• Imaging consistent with end-stage osteoarthritis
• Inadequate relief after other interventions (which may include prior injections)

How do other injections fit alongside biologics?

Orthobiologic reviews separate PRP and cell-based products (adipose- or marrow-derived) from more traditional injectables such as hyaluronic acid (HA). In most pathways, HA and similar options are discussed primarily for symptom control, rather than as biologic preparations intended to support endogenous repair signalling.

A similar “symptom-control” framing often applies to non-biologic fillers and anti-inflammatory injections that may be discussed in hip clinics. For example, Lincolnshire Hip lists Arthrosamid for hip arthritis and ChondroFiller for focal cartilage problems as part of its injection pathway (with PRP currently positioned for selected groin/adductor conditions rather than as its main intra-articular hip OA injection). The key practical point is that these options are not interchangeable: they differ in intent (scaffold vs filler vs biologic signalling), evidence base and appropriateness for a given pattern of hip disease.

Lincolnshire Hip pathway (one practical note)

Lincolnshire Hip describes “two paths through hip pain”: an injection-led route when surgery is not yet the right answer, and hip replacement when it is. Consultations and injections are delivered locally in Grantham and Sleaford, with hip replacement surgery undertaken in London as a separate pathway when required.

A simple way to decide what’s next

• If imaging suggests earlier-to-moderate hip osteoarthritis and the main goal is to stay active for the next 6–24 months, a biologic hip injection is often considered as a symptom-improving, time-buying step—accepting that results vary and some hips still progress to replacement within 1–3 years.
• If symptoms are present but still manageable and trending in the right direction over an 8–12 week period, watchful waiting (with continued rehabilitation and load management) is often the lower-risk next step.
• If pain is constant, sleep is repeatedly disrupted, function is markedly reduced, and imaging is end-stage, hip replacement is more commonly the definitive option because it addresses the structural problem directly.
• If there is a mismatch between scan severity and pain severity, the next sensible step is usually a consultant-led hip assessment to confirm the pain source and align treatment with the hip joint findings and priorities.

1. [1] Orthobiologic injections for hip osteoarthritis: A systematic review of clinical outcomes. (2025). https://doi.org/10.52965/001c.151461 https://doi.org/10.52965/001c.151461
2. [2] Orthobiologic injections for the treatment of hip osteoarthritis: A systematic review. (2022). https://doi.org/10.3390/jcm11226663 https://doi.org/10.3390/jcm11226663
3. [3] Is intra-articular injection of autologous micro-fragmented adipose tissue effective in hip osteoarthritis? A three year follow-up. (2022). https://doi.org/10.1007/s00264-022-05611-x https://doi.org/10.1007/s00264-022-05611-x